战斗MS:一个基于人口的观察性队列研究,针对多发性硬化症疗法与rituximab相比的益处风险平衡
Fredrik Piehl1,2,3, Peter Alping1,4, Suvi Virtanen4
1Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Annals of neurology
|June 26, 2024
概括
利图西马布的疗效与已批准的多发性硬化症 (MS) 疗法相提并论,复发率较低,治疗持续性更好. 然而,它与严重感染的风险增加有关,特别是在治疗转换后.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 多发性硬化症 (MS) 管理涉及各种疾病修饰疗法 (DMT).
- 利图西马布用于非标签的复发性复发性MS (RRMS).
- 对Rituximab与已批准的MS疗法进行比较的现实世界数据有限.
研究的目的:
- 为了比较非标签Rituximab的有效性,安全性和耐受性与已批准的MS疗法.
- 评估Rituximab对残疾恶化,疾病活性和RRMS患者报告结果的影响.
- 评估Rituximab的安全性,包括感染等严重不良事件.
主要方法:
- 2011-2018年期间,瑞典一项基于人口的队列研究,对2,449名 (首次开始治疗) 和2,463名 (转换治疗) RRMS患者 (18至75岁) 进行了研究.
- 利图西马布与经常使用的,MS批准的疗法进行了比较.
- 主要结局:12个月确认残疾恶化和MS影响量-29 (MSIS-29) 评分变化. 二次结局:复发,停止治疗,严重的不良事件. 分析使用治疗意图,并根据共变量进行调整.
主要成果:
- 在Rituximab和已批准的疗法之间,3年残疾恶化没有显著差异 (第一个疗法为9.1%,切换为5.1%).
- 利图西马布显示MSIS-29得分 (身体/心理) 得到改善,复发率降低,治疗持久性更高.
- 在治疗切换后观察到更高的医院治疗感染率与rituximab,但不是作为第一疗法.
结论:
- 非标签的Rituximab在预防残疾进展方面显示出与已批准的MS疗法相比具有可比的有效性.
- 利图西马布减少了炎症活动,改善了治疗的持续性,但增加了严重感染的风险,特别是在切换疗法时.
- 现实世界的证据支持Rituximab在MS管理中的作用,并仔细考虑其安全性.
相关概念视频
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...